MyHep All

MyHep All Tablet Uses Benefits and Side Effects

MyHep All (sofosbuvir 400mg + velpatasvir 100mg) is a fixed-dose combination (FDC) drug recommended against chronic hepatitis C viral (HCV) infection in adults. MyHep All (sofosbuvir 400mg + velpatasvir 100mg) is indicated for patients suffering from HCV genotype 1 to 6.

MyHep All (sofosbuvir 400 mg + velpatasvir 100 mg) is regarded as one of the most potent anti-HCV agents attaining 93-99% sustained virologic response (SVR) after 12 weeks of therapy based on genotype and the levels of cirrhosis.

What is Chronic Hepatitis C

Chronic hepatitis C is a persistent viral infection affecting the liver. Chronic hepatitis C is primarily transmitted through blood contact, such as sharing needles or receiving tainted blood transfusions. Over time, it can lead to liver damage, cirrhosis, and even liver cancer. Symptoms may be mild or absent initially, but can progress to fatigue, jaundice, and abdominal pain. Treatments are available to manage the infection and prevent complications.

FDC combination (sofosbuvir + velpatasvir) imparts advantages such as,

• Treatment of almost all genotypes (1-6) of HCV infection
• More than 90% of SVR in HCV patients with scarring of the liver (cirrhosis) in all genotypes

The FDC combination belongs to the class of direct-acting antiviral (DAA) drugs which explicitly inhibits a specific type of protein (RNA polymerase) that stops the multiplication (RNA replication) of cells reducing the viral load.

Administration of MyHep All (sofosbuvir 400mg + velpatasvir 100mg):

The drug is administered in a form a fixed-dose combination i.e. 1 tablet (sofosbuvir + velpatasvir combination) once daily. It can be taken with or without food.

Suggested dosage of MyHep All (sofosbuvir 400mg + velpatasvir 100mg) in patients with genotypes 1 to 6 HCV:

HCV disease type	Dosage	Duration (weeks)
No cirrhosis and cirrhosis with a functional system	MyHep All (sofosbuvir + velpatasvir) (1 tablet)	12
Cirrhosis with an unfunctional system	MyHep All (sofosbuvir + velpatasvir) plus ribavirin	12

Other properties of the FDC combination drug:

Properties	Sofosbuvir	Velpatasvir
Inhibited protein	Non-structural protein 5B (NS5B)	Non-structural protein 5A (NS5A)
Absorption in the system (Bio-availability	30 minutes to 2 hours	3 hours
Binding affinity with viral cells	61 to 65%	99%
Excretion time	40 minutes to 27 hours for 50% drug molecule	15 hours for 50% drug molecule

Note: The duration and frequency of dosage can be changed based on the initial experience of the patients. It is mostly dependent on the doctor’s judgement

When should Hepcvel (sofosbuvir 400mg + velpatasvir 100mg) be avoided or used cautiously?

• If patients are suffering from or had a history of Hepatitis B viral infection before taking sofosbuvir.
• If patients are suffering from kidney disease or undergoing dialysis or other severe medical condition
• If patients had a liver transplant before the initiation of dosage
• If patients have complications in the liver other than HCV infection
• If patients are pregnant and planning to breastfeed

Side-effects of Hepcvel (sofosbuvir 400mg + velpatasvir 100mg)

Most common side-effects:

• Headache
• Tiredness (Fatigue)

Serious side-effects: Slow heart rate (bradycardia)

Side-effects in HCV patients without cirrhosis or cirrhosis with a functional system:

• Physical weakness (Asthenia)
• Lack of sleep (Insomnia)
• Nausea
• Headache
• Tiredness

Side-effects in HCV patients with cirrhosis and an unfunctional system:

• Low count of red blood cells (RBCs) (Anemia)
• Lack of sleep
• Headache
• Diarrhea
• Nausea
• Tiredness

Uncommon side-effects: 

• Depression
• Severe rashes on the skin

Note:

• These are not all possible side-effects of Hepcvel (sofosbuvir 400mg + velpatasvir 100mg), please ask your doctor for more information regarding the same.
• We are also exporting to countries: South East Asia, South America, USA (California, Las Vegas, San Francisco), Eastern Europe (Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Macedonia, Poland, Republic of Kosovo, Republic of Moldova, Romania, Russia, Serbia, Slovak Republic, Slovenia, Malaysia, Indonesia, Philippines, Venezuela and Korea.) and many more…